Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
Helei Hou,* Kang Qin,* Yu Liang, Chuantao Zhang, Dong Liu, Haiping Jiang, Kewei Liu, Jingjuan Zhu, Hongying Lv, Tianjun Li, Xiaochun ZhangDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People’s Republic of China*These authors cont...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-06-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/concurrent-tp53-mutations-predict-poor-outcomes-of-egfr-tki-treatments-peer-reviewed-article-CMAR |
| _version_ | 1811311557202673664 |
|---|---|
| author | Hou H Qin K Liang Y Zhang C Liu D Jiang H Liu K Zhu J Lv H Li T Zhang X |
| author_facet | Hou H Qin K Liang Y Zhang C Liu D Jiang H Liu K Zhu J Lv H Li T Zhang X |
| author_sort | Hou H |
| collection | DOAJ |
| description | Helei Hou,* Kang Qin,* Yu Liang, Chuantao Zhang, Dong Liu, Haiping Jiang, Kewei Liu, Jingjuan Zhu, Hongying Lv, Tianjun Li, Xiaochun ZhangDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People’s Republic of China*These authors contributed equally to this work Purpose: The study investigated the impact of TP53 mutations on the clinical efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs) in Chinese patients with advanced or recurrent non-small-cell lung cancer (NSCLC).Patients and methods: Tissues from 163 NSCLC patients at the Affiliated Hospital of Qingdao University were analyzed by next-generation sequencing (NGS) to determine the mutational status of EGFR and concurrent genetic alterations. TP53 mutations were evaluated in relation to baseline patient characteristics and treatment outcomes (progression-free survival [PFS], overall survival [OS], objective response rate [ORR] and disease control rate [DCR]).Results: Among 163 patients with advanced NSCLC, 77 were identified as EGFR-mutant (47.2%). Six patients who did not receive TKI treatment were excluded. Among the remaining 71 patients with EGFR genetic alterations, the frequency of pathogenic TP53 mutations was 60.6% (43/71), while other concurrent mutations were rare events. Markedly shorter median PFS (mPFS) (6.5 versus 14.0 months, P=0.025) and median OS (mOS) (28.0 versus 52.0 months, P=0.023) were observed in TP53-mut patients than in TP53-wt controls. The overall DCR and ORR of TP53-mutant patients were both lower than those of the TP53-wt cases (DCR: 76.7% versus 89.3%, P=0.160; ORR: 25% versus 28%, P=0.374). Differences in prognosis were significant, especially in the subgroup of patients with TP53 non-missense mutations, non-disruptive mutations, mutations in exon 6, mutations in exon 7 and mutations in the non-DBD region among all TP53 mutations.Conclusion: TP53 mutations reduce responsiveness to TKIs and worsen the prognosis of EGFR-mutant NSCLC patients, especially for those with non-missense mutations and non-disruptive mutations, as well as mutations in exon 6, exon 7 and non-DBD region, thus acting as an independent predictor of poor outcome in advanced NSCLC patients treated with first-generation TKI therapy. Our study also suggests that TP53 mutation might be involved in primary resistance to EGFR-TKIs in Chinese NSCLC patients.Keywords: TP53, epidermal growth factor receptor, tyrosine kinase inhibitors, non-small-cell lung cancer, mutation, exon |
| first_indexed | 2024-04-13T10:20:02Z |
| format | Article |
| id | doaj.art-c5259d91cfd041b9b21dfb1bbfabefc4 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-13T10:20:02Z |
| publishDate | 2019-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-c5259d91cfd041b9b21dfb1bbfabefc42022-12-22T02:50:32ZengDove Medical PressCancer Management and Research1179-13222019-06-01Volume 115665567546579Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLCHou HQin KLiang YZhang CLiu DJiang HLiu KZhu JLv HLi TZhang XHelei Hou,* Kang Qin,* Yu Liang, Chuantao Zhang, Dong Liu, Haiping Jiang, Kewei Liu, Jingjuan Zhu, Hongying Lv, Tianjun Li, Xiaochun ZhangDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People’s Republic of China*These authors contributed equally to this work Purpose: The study investigated the impact of TP53 mutations on the clinical efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs) in Chinese patients with advanced or recurrent non-small-cell lung cancer (NSCLC).Patients and methods: Tissues from 163 NSCLC patients at the Affiliated Hospital of Qingdao University were analyzed by next-generation sequencing (NGS) to determine the mutational status of EGFR and concurrent genetic alterations. TP53 mutations were evaluated in relation to baseline patient characteristics and treatment outcomes (progression-free survival [PFS], overall survival [OS], objective response rate [ORR] and disease control rate [DCR]).Results: Among 163 patients with advanced NSCLC, 77 were identified as EGFR-mutant (47.2%). Six patients who did not receive TKI treatment were excluded. Among the remaining 71 patients with EGFR genetic alterations, the frequency of pathogenic TP53 mutations was 60.6% (43/71), while other concurrent mutations were rare events. Markedly shorter median PFS (mPFS) (6.5 versus 14.0 months, P=0.025) and median OS (mOS) (28.0 versus 52.0 months, P=0.023) were observed in TP53-mut patients than in TP53-wt controls. The overall DCR and ORR of TP53-mutant patients were both lower than those of the TP53-wt cases (DCR: 76.7% versus 89.3%, P=0.160; ORR: 25% versus 28%, P=0.374). Differences in prognosis were significant, especially in the subgroup of patients with TP53 non-missense mutations, non-disruptive mutations, mutations in exon 6, mutations in exon 7 and mutations in the non-DBD region among all TP53 mutations.Conclusion: TP53 mutations reduce responsiveness to TKIs and worsen the prognosis of EGFR-mutant NSCLC patients, especially for those with non-missense mutations and non-disruptive mutations, as well as mutations in exon 6, exon 7 and non-DBD region, thus acting as an independent predictor of poor outcome in advanced NSCLC patients treated with first-generation TKI therapy. Our study also suggests that TP53 mutation might be involved in primary resistance to EGFR-TKIs in Chinese NSCLC patients.Keywords: TP53, epidermal growth factor receptor, tyrosine kinase inhibitors, non-small-cell lung cancer, mutation, exonhttps://www.dovepress.com/concurrent-tp53-mutations-predict-poor-outcomes-of-egfr-tki-treatments-peer-reviewed-article-CMARTP53Epidermal growth factor receptorTyrosine kinase inhibitorsNon-small-cell lung cancerMutationExon |
| spellingShingle | Hou H Qin K Liang Y Zhang C Liu D Jiang H Liu K Zhu J Lv H Li T Zhang X Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC Cancer Management and Research TP53 Epidermal growth factor receptor Tyrosine kinase inhibitors Non-small-cell lung cancer Mutation Exon |
| title | Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC |
| title_full | Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC |
| title_fullStr | Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC |
| title_full_unstemmed | Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC |
| title_short | Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC |
| title_sort | concurrent tp53 mutations predict poor outcomes of egfr tki treatments in chinese patients with advanced nsclc |
| topic | TP53 Epidermal growth factor receptor Tyrosine kinase inhibitors Non-small-cell lung cancer Mutation Exon |
| url | https://www.dovepress.com/concurrent-tp53-mutations-predict-poor-outcomes-of-egfr-tki-treatments-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT houh concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT qink concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT liangy concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT zhangc concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT liud concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT jiangh concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT liuk concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT zhuj concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT lvh concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT lit concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc AT zhangx concurrenttp53mutationspredictpooroutcomesofegfrtkitreatmentsinchinesepatientswithadvancednsclc |